[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Tennessee Graduate School of Medicine\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":318},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,37,63,84,108,136,156,197,216,245,272,299],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":4,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":25,"lastUpdatePostDateStruct":26,"startDateStruct":29,"completionDateStruct":31,"leadSponsor":33,"locationsCount":36},"100651716","whole-body-metabolic-activity-as-a-reflection-of-tumor-metabolic-dysregulation-and-a-predictor-of-treatment-response-in-ovarian-cancer-100651716",false,"NCT07764133","Whole Body Metabolic Activity as a Reflection of Tumor Metabolic Dysregulation and a Predictor of Treatment Response in Ovarian Cancer","Inclusion Criteria:\n\n1. Women\n2. Age \\>18 years\n3. Suspected of having epithelial ovarian cancer by the provider\n4. No prior cytotoxic therapy for ovarian cancer\n5. Surgical debulking is planned\n6. ECOG performance status 0-1\n\nExclusion Criteria:\n\n1. Inability to provide voluntary informed consent\n2. Received medical intervention for adverse effects of chemotherapy\n3. Circumstances and\u002For medical conditions that would limit compliance with study requirements and protocol, as determined by the principal investigators.\n4. Poorly controlled diabetes, hemoglobin A1C ≥9%","FEMALE","18 Years",{"count":18,"type":19},50,"ESTIMATED","OBSERVATIONAL","The primary objectives of the study are:\n\n1. To delineate commonly utilized tumor metabolic alterations in ovarian cancer. These metabolic alterations will be explored for potentially targetable pathways to restore chemotherapy responsiveness.\n2. To define the relationship between whole-body metabolic activity as measured via indirect calorimetry with ex vivo measure of tumor metabolic activity.\n\n   The secondary objectives of the study are:\n3. To evaluate longitudinal changes in whole-body metabolic activity over the course of cytotoxic chemotherapy and evaluate these changes as they relate to oncologic outcomes and treatment-free interval.\n4. To examine the impact of tumor metabolic alterations on healthy non-malignant tissues and serum metabolites.\n5. An additional exploratory objective is to collect data that will contribute to a more holistic understanding of the whole-body metabolic effects of ovarian cancer. Based on prior studies, surveys have been an effective method for capturing the social, psychological, and behavioral factors associated with the disease. It is possible that changes in metabolism and inflammation are mediated by these psychosocial factors that ultimately impact response to cancer therapy.\n\nIt is hypothesized that whole-body metabolic activity as measured via indirect calorimetry can be utilized as a non-invasive surrogate to reflect tumor metabolic dysregulation in patients with ovarian cancer. Moreover, it is hypothesized that there will be an inverse relationship between treatment-free interval and the metabolic rate when measured at a whole-body level and an increased rate of glycolysis when measured within the tumor microenvironment. To address these hypotheses, the study will pursue the specific aims listed above.",[23],"Epithelial Ovarian Cancer","RECRUITING","2026-08-14",{"date":27,"type":28},"2026-08-17","ACTUAL",{"date":30,"type":28},"2026-05-13",{"date":32,"type":19},"2028-05-13",{"name":34,"class":35},"University of Tennessee Graduate School of Medicine","OTHER",1,{"id":38,"slug":39,"hasResults":11,"nctId":40,"briefTitle":41,"officialTitle":42,"acronym":4,"eligibilityCriteria":43,"healthyVolunteers":11,"sex":44,"minAge":45,"maxAge":4,"enrollmentInfo":46,"targetDuration":4,"studyType":48,"phases":49,"briefSummary":51,"conditions":52,"keywords":54,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":25,"lastUpdatePostDateStruct":57,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":36},"100648511","phase-4-efficacy-of-nebulized-long-acting-bronchodilators-formoterol-and-revefenacin-vs-short-acting-bronchodilators-albuterol-and-ipratropium-in-patients-presenting-to-the-emergency-department-with-acute-exacerbation-of-copd-ecopd-100648511","NCT07721922","Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Patients Presenting to the Emergency Department With Acute Exacerbation of COPD (ECOPD)","Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Patients Presenting to the Emergency Department With Acute Exacerbation of COPD (ECOPD): A Phase IV, Prospective, Randomized, Blinded, Parallel-group Trial","Inclusion Criteria:\n\n1. Male or Female\n2. Any Race\n3. ≥ 40 years of age\n4. History of COPD based on EMR or confirmed verbally by the patient\n5. Presenting to the ED with a primary diagnosis of ECOPD or acute respiratory failure with a secondary diagnosis of COPD\n6. Able to understand and comply with study procedures\n7. Willingness to sign and date an Informed Consent Form\n\nExclusion Criteria:\n\n1. Patients unable or unwilling to sign an informed consent or cooperate with study procedures\n2. Patients who are hypersensitive to Formoterol or Revefenacin\n3. Patients who are intubated, have tracheotomy, are receiving mechanical ventilation by mask or artificial airway\n4. Patients who have previously participated in the study\n5. Patients, in the opinion of the investigators, who are rapidly decompensating and are immediately in need, or will soon need, ventilator support based on:\n\n   i. Inability to maintain respiratory effort ii. Cyanosis iii. Hemodynamic instability iv. Deterioration in mental status\n6. Patients who, per the investigator, have unstable cardiovascular disease (e.g., uncontrolled hypertension, unstable angina, recent MI (within 12 weeks), ventricular arrhythmia, or decompensated heart failure)\n7. Patients with a current diagnosis of lung cancer requiring treatment\n8. Pulmonary diseases other than COPD, or lobar pneumonia\n9. Patients with acute psychiatric illness deemed significant by the investigator\n10. Patients with a history of glaucoma deemed significant by the investigator\n11. History of urinary retention deemed significant by the investigator\n12. Women who are pregnant or breastfeeding","ALL","40 Years",{"count":47,"type":19},280,"INTERVENTIONAL",[50],"PHASE4","The primary aim is to determine whether nebulized Formoterol twice daily plus Revefenacin once daily is non-inferior to standard-of-care nebulized Albuterol and Ipratropium therapy four times daily in relieving dyspnea among patients with ECOPD presenting to the ED and requiring hospitalization, as measured by the Modified Borg Dyspnea Scale.\n\nThe hypothesize is that patients in the ED for ECOPD, improvement in symptoms, safety, and length of ED or hospital stay after treatment with nebulized Revefenacin and Formoterol will be non-inferior to the Albuterol and Ipratropium combination. The long-acting bronchodilator regimen will provide comparable symptom control with fewer total drug doses compared with standard treatment with short-acting bronchodilators, namely, nebulized Albuterol and Ipratropium. To the best of our knowledge, this will be the first prospective, randomized, double-blind investigation to compare a combination of long-acting nebulized LAMA\u002FLABA bronchodilators with a standard-of-care combination of short-acting nebulized SAMA\u002FSABA bronchodilators in patients with an ECOPD in the ED\u002Fhospital setting.",[53],"COPD Exacerbation",[55],"ECOPD","NOT_YET_RECRUITING",{"date":27,"type":28},{"date":59,"type":19},"2026-09-01",{"date":61,"type":19},"2028-09-01",{"name":34,"class":35},{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":67,"acronym":4,"eligibilityCriteria":68,"healthyVolunteers":11,"sex":44,"minAge":16,"maxAge":4,"enrollmentInfo":69,"targetDuration":4,"studyType":48,"phases":71,"briefSummary":73,"conditions":74,"keywords":76,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":25,"lastUpdatePostDateStruct":78,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":36},"100608708","improved-outcomes-with-pre-procedure-shockwave-ivl-of-common-femoral-artery-access-site-prior-to-large-bore-access-and-pre-closure-100608708","NCT07205068","Improved Outcomes With Pre-Procedure Shockwave IVL of Common Femoral Artery Access Site Prior to Large Bore Access and Pre-Closure","Inclusion Criteria:\n\n1. \\>18 years of age\n2. Patient with a diagnosis of severe aortic stenosis undergoing TAVR\n3. Participants must be able to read and understand study procedures\n4. Willing to participate and sign an ICF\n5. Patients with \\> 90-degree arc of calcium at the large bore access site per CT documentation\n\nExclusion Criteria:\n\n1. Unable to understand study procedures\n2. Unwilling to give consent\n3. Patients with cognitive impairments that can affect their ability to give consent\n4. Unfavorable calcium distribution of femoral artery",{"count":70,"type":19},100,[72],"NA","The primary purpose of this study is to observe reduced access site complications in patients with heavily calcified common femoral arteries requiring Transcatheter Aortic Valve Replacement (TAVR)",[75],"Aortic Stenosis",[75,77],"Transcatheter aortic valve replacement",{"date":27,"type":28},{"date":80,"type":28},"2025-10-04",{"date":82,"type":19},"2028-10-04",{"name":34,"class":35},{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":4,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":44,"minAge":45,"maxAge":4,"enrollmentInfo":91,"targetDuration":4,"studyType":48,"phases":93,"briefSummary":94,"conditions":95,"keywords":97,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":25,"lastUpdatePostDateStruct":102,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":36},"100603235","phase-4-compare-the-effects-of-nebulizer-versus-inhaler-based-therapy-for-copd-using-long-acting-bronchodilators-100603235","NCT07133880","Compare the Effects of Nebulizer Versus Inhaler Based Therapy for COPD Using Long-acting Bronchodilators","Differentiating the Effects of Long-acting Bronchodilators Administered by Nebulizer Versus Dry Powder Inhaler in Symptomatic Patients With Chronic Obstructive Pulmonary Disease","Inclusion Criteria:\n\n1. Age \\> 40 years\n2. Either sex\n3. Current smoker or past cigarette smoking history of \\> 10 pack-years\n4. Symptoms of COPD (cough, sputum production, shortness of breath)\n5. Modified Medical Research Council Dyspnea Scale (mMRC) score ≥2 or CAT score ≥10 at Screening\u002FRun-in visit\n6. A PIFR \\> 30 at screening\n7. FEV1\u002FFVC ratio \\\u003C 70% (within the past 12 months)\n8. Residual volume (RV) ≥ 120% predicted (within the past 12 months\n\nExclusion Criteria:\n\n1. Diagnosis of asthma (Verification via medical record and\u002For patient report)\n2. Previously diagnosed atrial fibrillation with rapid ventricular response (heart rate \\> 110 bpm) or ventricular arrhythmia (ventricular tachycardia) (Verification via medical record and\u002For patient report)\n3. Acute myocardial infarction within 12 weeks of patient study registration (Verification via medical record and\u002For patient report)\n4. Acute exacerbation of congestive heart failure (Verification via medical record and\u002For patient report)\n5. Acute exacerbation of COPD within 8 weeks (Verification via medical record and\u002For patient report)\n6. Recent (within 8 weeks) h\u002Fo eye surgery (Verification via medical record and\u002For patient report)\n7. Uncontrolled glaucoma (Verification via medical record and\u002For patient report)\n8. Known diagnosis of liver cirrhosis (Verification via medical record and\u002For patient report)\n9. Known diagnosis of chronic renal insufficiency (defined as a previous serum creatinine \\> 2.5 mg\u002FdL - Verification via medical record and\u002For patient report)\n10. Intolerance to any of the study drugs\n11. Patients receiving long-term azithromycin\n12. Planned surgery requiring hospital admission within 3 months\n13. Currently enrolled in a pulmonary rehabilitation program\n14. Inability to give informed consent\n15. Pregnant or nursing women or women of childbearing potential not using a medically approved means of contraception (i.e., oral contraceptives, intrauterine devices, diaphragm, or subdermal implants)\n16. Inability to understand instructions or comply with the study protocol\n17. Participation in another investigational drug clinical trial within 30 days of patient study registration\n\nMedical history can be confirmed by medical records and\u002For verbal confirmation from patients. However, Inclusion criteria 6 \\& 7 must be verified by a previous PFT report dated within 6 months of screening",{"count":92,"type":19},72,[50],"The purpose of this study is to compare the effectiveness of inhaled bronchodilators delivered via nebulizers vs. dry powder inhalers (DPIs) in symptomatic participants with Chronic Obstructive Pulmonary Disease (COPD) who have airflow obstruction (FEV1\u002FFVC ≤ 70%) and show significant air trapping (RV ≥ 120% of predicted).\n\nThe investigators hypothesize that, in patients with symptomatic COPD, therapy with a long-acting anti muscarinic agent\u002Flong-acting beta agonist (LAMA\u002FLABA) combination administered by nebulizer will improve hyperinflation (increase in inspiratory capacity and reduction in residual volume) and reduce symptoms related to COPD to a greater extent than LAMA\u002FLABA therapy given by a DPI.\n\nThe study aims to demonstrate the following:\n\n1. Compare the values of inspiratory capacity (IC) and residual volume (RV) in patients receiving LAMA\u002FLABA by DPI with those receiving LAMA\u002FLABA by nebulizer\n2. Compare patient reported outcomes (COPD Assessment Test (CAT score), Baseline\u002FTransition Dyspnea Index (BDI\u002FTDI) and the St. George Respiratory Questionnaire (SGRQ) in symptomatic patients with COPD receiving LAMA\u002FLABA by DPI with those receiving LAMA\u002FLABA by nebulizer",[96],"COPD (Chronic Obstructive Pulmonary Disease)",[98,99,100,101],"Chronic Obstructive Pulmonary Disease","COPD","Nebulizer","Dry Powder Inhaler",{"date":27,"type":28},{"date":104,"type":28},"2023-12-05",{"date":106,"type":19},"2026-12-01",{"name":34,"class":35},{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":115,"sex":44,"minAge":16,"maxAge":4,"enrollmentInfo":116,"targetDuration":4,"studyType":48,"phases":118,"briefSummary":120,"conditions":121,"keywords":123,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":36},"100512389","phase-1-a-phase-1-study-of-99mtc-p514-in-healthy-volunteers-and-patients-with-al-or-attr-systemic-amyloidosis-100512389","NCT05951816","A Phase 1 Study of 99mTc-p5+14 in Healthy Volunteers and Patients With AL or ATTR Systemic Amyloidosis","Phase 1 Study to Investigate the Dosimetry and Biodistribution of a Single Intravenous Administration of 99mTc-p5+14 Using SPECT\u002FCT Imaging and Planar Gamma Scintigraphy in Healthy Volunteers and Patients With AL or ATTR Systemic Amyloidosis","Inclusion Criteria:\n\nPART 1\n\n1\\) Understand the study procedures and agree to participate in the study by giving written informed consent..\n\n2\\) Be male or female \\>18 years of age. 3) Women of child-bearing potential (WOCBP) (those who have not been surgically sterilized, are not postmenopausal \\[i.e., last menstrual period \\>2 years ago without pharmaceutical intervention\\], and women who are fertile) must have a negative pregnancy test prior within 24 h prior to infusion.\n\n4\\) WOCBP who are not exclusively in same-sex relationships and male participants with female sexual partners who are WOCBP must agree to use adequate contraceptive methods, defined as use of a condom by the male partner combined with use of a highly effective method of contraception by the female partner, for at least 2.5 days after injection of 99mTc-p5+14.\n\n5\\) Be a healthy volunteer (n=3) or have a confirmed diagnosis of systemic amyloidosis (n=2) based on either a histologic confirmation with a biopsy containing deposits of apple-green birefringent, Congophilic material with aberrant organ-specific biomarkers indicating amyloid involvement, physical examination, or imaging study.\n\n6\\) Healthy volunteers must also meet inclusion criteria for Part 3. PART 2\n\n1. Understand the study procedures and agree to participate in the study by giving written informed consent.\n2. Be male or female \\>18 years of age.\n3. WOCBP (those who have not been surgically sterilized, are not postmenopausal \\[i.e., last menstrual period \\>2 years ago without pharmaceutical intervention\\], and women who are fertile) must have a negative pregnancy test prior within 24 h prior to infusion.\n4. WOCBP who are not exclusively in same-sex relationships and male participants with female sexual partners who are WOCBP must agree to use adequate contraceptive methods, defined as use of a condom by the male partner combined with use of a highly effective method of contraception by the female partner, for at least 2.5 days after injection of 99mTc-p5+14.\n5. Have one of the following:\n\n   1. a confirmed diagnosis of systemic AL amyloidosis, based on either a histologic confirmation of a cardiac or extracardiac biopsy containing deposits of apple-green birefringent, Congophilic material AND imaging parameters (ECHO or CMR) indicative of cardiac involvement.\n   2. a confirmed diagnosis of systemic ATTR amyloidosis, based on either a histologic confirmation of a cardiac biopsy containing deposits of apple-green birefringent, Congophilic material or extracardiac biopsy and imaging parameters (ECHO or CMR or 99mTc-PYP) indicative of cardiac involvement, with no evidence of abnormal serum free light chains.\n6. Have a diagnosis of cardiac amyloidosis within 4 years of screening, or longer if contemporaneous clinical data indicates the persistent presence of cardiac amyloidosis.\n\nPART 3\n\n1. Understand the study procedures and agree to participate in the study by giving written informed consent.\n2. Be male or female \\>18 years of age.\n3. WOCBP (those who have not been surgically sterilized, are not postmenopausal \\[i.e., last menstrual period \\>2 years ago without pharmaceutical intervention\\], and women who are fertile) must have a negative pregnancy test prior within 24 h prior to infusion.\n4. WOCBP who are not exclusively in same-sex relationships and male participants with female sexual partners who are WOCBP must agree to use adequate contraceptive methods, defined as use of a condom by the male partner combined with use of a highly effective method of contraception by the female partner, for at least 2.5 days after injection of 99mTc-p5+14.\n5. Be in good general health, as determined by no clinically significant findings (including Type 2 diabetes mellitus) in the opinion of the Investigator from review of the medical history.\n6. Does not have a diagnosis of amyloidosis nor has a first- or second-degree relative (parent, sibling, child, aunt, uncle, niece, nephew) with confirmed or suspected familial amyloidosis.\n\nPART 4\n\n1. Understand the study procedures and agree to participate in the study by giving written informed consent.\n2. Be male or female \\>18 years of age.\n3. Women of child-bearing potential (those who have not been surgically sterilized, are not postmenopausal \\[i.e., last menstrual period \\>2 years ago without pharmaceutical intervention\\], and women who are fertile) must have a negative pregnancy test prior within 24 h prior to infusion.\n4. WOCBP who are not exclusively in same-sex relationships and male participants with female sexual partners who are WOCBP must agree to use adequate contraceptive methods, defined as use of a condom by the male partner combined with use of a highly effective method of contraception by the female partner, for at least 2.5 days after injection of 99mTc-p5+14.\n5. Has a confirmed diagnosis of systemic ATTR amyloidosis, based on either a histologic confirmation of a cardiac biopsy containing deposits of apple-green birefringent, Congophilic material or extracardiac biopsy and imaging parameters (ECHO or CMR), or abnormal serum biomarkers indicative of cardiac involvement, with no evidence of abnormal serum free light chains.\n6. Has a diagnosis of cardiac amyloidosis within 4 years of screening, or longer if contemporaneous clinical data indicates the persistent presence of cardiac amyloidosis.\n7. Has a negative 99mTc-PYP imaging study.\n\nExclusion Criteria:\n\nPARTS 1-4\n\n1. Due to annual dosimetry limitations, patients who have participated in another nuclear medicine amyloid imaging clinical trial protocol and received tracer injection in the last 6 months.\n2. Is pregnant or breast-feeding.\n3. Is mentally or legally incapacitated, has significant emotional problems at the time of the study, or has a history of psychosis.\n4. Receiving hemodialysis or peritoneal dialysis.\n5. Has severe claustrophobia or any medical condition that would prevent completion of the imaging protocol.\n6. Has any illness that, in the opinion of the Investigator, might confound the results of the study or pose additional risk to the subject.\n7. Has received heparin or heparin analogs (e.g., enoxaparin, dalteparin, fondaparinux) within seven (7) days prior to 99mTc-p5+14 administration.\n8. Have previously received any dose of p5+14, in any form.\n9. Have a serum AST \\>2x the upper limit of normal or 80 IU\u002FL AND total bilirubin \\> 1.5x the upper limit of normal or 1.8 mg\u002FdL within the previous six months of enrollment.\n10. Have a serum ALT \\>2x the upper limit of normal or 64 IU\u002FL AND total bilirubin \\> 1.5x the upper limit of normal or 1.8 mg\u002FdL within the previous six months of enrollment.\n11. Have a QTc interval, using Bazett's formula (QTcB) of \\>530 ms, measured within six months prior to enrollment, or assessed prior to injection.",true,{"count":117,"type":19},31,[119],"PHASE1","This study will investigate 99mTc-p5+14, an amyloid-reactive synthetic peptide, p5+14, radiolabeled with technetium-99m, as a radiotracer for detecting paamyloid deposits in patients with AL or ATTR-associated systemic amyloidosis, notably with cardiac involvement.",[122],"Systemic Amyloidosis",[124,125,126,127],"Amyloidosis","p5+14","SPECT imaging","iodine-124-evuzamitide","2026-07-22",{"date":130,"type":28},"2026-07-24",{"date":132,"type":28},"2023-09-18",{"date":134,"type":19},"2027-06",{"name":34,"class":35},{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":140,"acronym":4,"eligibilityCriteria":141,"healthyVolunteers":115,"sex":44,"minAge":16,"maxAge":4,"enrollmentInfo":142,"targetDuration":4,"studyType":48,"phases":144,"briefSummary":145,"conditions":146,"keywords":4,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":36},"100609394","planning-together-a-couple-based-multi-level-prenatal-contraceptive-education-program-for-economically-marginalized-families-100609394","NCT07214012","Planning Together: A Couple-based, Multi-level Prenatal Contraceptive Education Program for Economically Marginalized Families","Inclusion Criteria:\n\nPatient Inclusion Criteria:\n\n1. \\> 20 weeks pregnant, age 18+\n2. The pregnant person has an available romantic partner, and the couple was able to get pregnant on their own or will be able to after the delivery\n3. separately, the pregnant person reports being in a sexually, psychologically and physically safe relationship\n4. English-speaking\n\nRomantic Partner Inclusion Criteria:\n\n1. 18 years of age and older\n2. Cohabiting with the patient; in a romantic relationship with patient\n3. Capable of getting the patient pregnant after delivery\n4. Does not need to be the biological father of the current pregnancy\n5. English-speaking (in order to take part in the interview as the interviewer does not speak Spanish)\n\nExclusion Criteria:\n\nPatient Exclusion Criteria:\n\n1. Participant is under the age of 18\n2. Documented cognitive impairment or psychiatric condition in pregnant person's medical record (e.g., severe learning disability, dementia, current psychotic disorder, suicidality)\n3. Participation in a concurrent contraceptive education intervention\n4. The pregnant person has a high-risk medical condition\n\nRomantic Partner Exclusion Criteria:\n\n1. Less than 18 years of age\n2. Are not cohabiting with the patient; not in a romantic relationship with patient\n3. Not capable of getting the patient pregnant after delivery",{"count":143,"type":19},60,[72],"The goal of this pilot trial is to examine the feasibility and acceptability of the Planning Together protocol\n\nThe hypothesis of this study are\n\n1. The study will achieve feasibility, demonstrated by ≥80% study accrual (30 couples in 8 months), ≥75% protocol adherence, and ≥75% (e.g., education workbook completion)\n2. The intervention will be acceptable, with \\>80% of participants reporting satisfaction with Planning Together.\n3. Patterns of primary outcomes (contraceptive knowledge, communication quality, community referral utilization) and secondary outcomes (agreed contraceptive plan, consistent contraceptive usage and satisfaction, psychological distress, and Short Interpregnancy Intervals \\[SII\\]) will suggest benefits of the intervention.",[147,148],"Short Interpregnancy Intervals","Maternal Health Disparities",{"date":150,"type":28},"2026-05-18",{"date":152,"type":28},"2025-11-25",{"date":154,"type":19},"2026-10-14",{"name":34,"class":35},{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":162,"eligibilityCriteria":163,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":164,"enrollmentInfo":165,"targetDuration":166,"studyType":20,"phases":4,"briefSummary":167,"conditions":168,"keywords":181,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":36},"100636441","cardiometabolic-disease-and-substrate-metabolism-100636441","NCT07565727","Cardiometabolic Disease and Substrate Metabolism","Cardiometabolic Disease, Substrate Metabolism, and Abnormal Placental Pathology: a Multimodal Maternal-Fetal Study","CAP","Inclusion Criteria:\n\n* Age 18-45\n* Any pre-pregnancy BMI\n* At least one high risk OR one moderate risk factor for pre-eclampsia based on ACOG and USPSTF guidelines\n* Willingness to adhere to aspirin therapy\n* Willingness to undergo 2h OGTT for serum collection in addition to survey collection, indirect calorimetry, body composition measures, neonatal measures, etc.\n* Gestational age at enrollment \\\u003C18 weeks\n* Ability to speak, read, and communicate via English\n\nExclusion Criteria:\n\n* Type 2 Diabetes Mellitus\n* Type 1 Diabetes Mellitus\n* Current gestational diabetes mellitus\n* Current\u002Factive platelet disorder or bleeding diathesis (thrombocytopenia of any etiology, idiopathic thrombocytopenic purpura\u002FITP, thrombotic thrombocytopenic purpura\u002FTTP, von Willebrand disease, etc.)\n* Thrombophilia\n* Current use of NSAID for other indication (indomethacin, ibuprofen, etc.)\n* Current use of other immune-modulating agents and biologics (hydroxychloroquine, azathioprine, 6-mercaptopurine, IL-6 inhibitors, etc.)\n* Current or recent use of steroids\n* Current use of prophylactic or therapeutic anticoagulation\n* Medical contraindication to aspirin therapy\n* Molar pregnancy\n* Renal disease\n* Inability or unwillingness to give informed consent\n* Current psychiatric illness\u002Fsocial situation that would limit compliance with study requirements, as determined by the principal investigators","45 Years",{"count":18,"type":19},"9 Months","This study's primary purpose is to determine the potential relationship between cardiometabolic disease, specifically insulin resistance (HOMA-IR), and maternal lipid oxidation.",[169,170,171,172,173,174,175,176,177,178,179,180],"Preeclampsia","Gestational Diabetes Mellitus (GDM)","Preeclampsia (PE)","Preeclampsia (PE) Risk","Gestational Diabetes","Gestational Diabetes Mellitus in Pregnancy","Cardiometabolic Diseases","Insulin Resistance","Placental Dysfunction","Pregnancy","Pregnancy Complications","Gestational Complications",[182,183,169,173,184,185,186,187,188],"Cardiometabolic disease","Substrate metabolism","Insulin resistance","HOMA-IR","Lipid oxidation","Placental dysfunction","Chorangiosis","2026-04-27",{"date":191,"type":28},"2026-05-04",{"date":193,"type":28},"2025-12-10",{"date":195,"type":19},"2027-08",{"name":34,"class":35},{"id":198,"slug":199,"hasResults":11,"nctId":200,"briefTitle":201,"officialTitle":201,"acronym":202,"eligibilityCriteria":203,"healthyVolunteers":11,"sex":44,"minAge":16,"maxAge":4,"enrollmentInfo":204,"targetDuration":4,"studyType":48,"phases":206,"briefSummary":207,"conditions":208,"keywords":4,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":210,"startDateStruct":212,"completionDateStruct":213,"leadSponsor":215,"locationsCount":36},"100610119","revasc-pad-restricted-vascular-exercise-for-peripheral-arterial-disease---a-feasibility-study-at-university-of-tennessee-medical-center-100610119","NCT07223437","REVASC-PAD: REstricted VASCular Exercise for Peripheral Arterial Disease - A Feasibility Study at University of Tennessee Medical Center","REVASC-PAD","Inclusion Criteria:\n\n1. 18 years of age or older\n2. Diagnosed peripheral arterial disease with stable claudication (symptomatic presentation unchanged for 6 months)\n3. Ankle-brachial index (ABI) between 0.4 and 0.9.\n4. Eligible referral to cardiovascular or pulmonary rehabilitation\n5. Prior revascularization permitted if symptoms are stable and other criteria are met\n\nExclusion Criteria:\n\n1. Recent change in resting ECG suggesting significant ischemia, recent myocardial infarction (within 2 weeks), or another acute cardiac event\n2. Unstable angina\n3. Uncontrolled cardiac arrhythmias\n4. Symptomatic severe aortic stenosis or other significant valvular disease\n5. Decompensated symptomatic heart failure\n6. Acute pulmonary embolism or infarction\n7. Acute noncardiac disorder likely to interfere with or be worsened by exercise (e.g., infection, thyrotoxicosis)\n8. Acute myocarditis or pericarditis\n9. Acute thrombophlebitis\n10. Physical disability precluding safe or adequate exercise performance\n11. Significant electrolyte abnormalities\n12. Clinically significant tachyarrhythmias or bradyarrhythmias\n13. High-degree atrioventricular block\n14. Atrial fibrillation with uncontrolled ventricular response\n15. Hypertrophic obstructive cardiomyopathy with resting left ventricular outflow gradient of \\>25 mmHg\n16. Known active aortic dissection\n17. Severe resting arterial hypertension (SBP\\>200mmHg or DBP \\>110 mmHg)\n18. Mental impairment preventing cooperation with study procedures\n19. Current pregnancy\n20. Moderate to severe peripheral neuropathy\n21. Open wounds or compromised skin near BFR cuff site\n22. Active DVT or thromboembolic event within the past year",{"count":205,"type":19},81,[72],"The purpose of this study is to evaluate the effects of Blood Flow Restriction (BFR) training on walking function, health-related quality of life, and safety among adults with Peripheral Arterial Disease (PAD).\n\nThe main aims of the study are:\n\n1. Evaluate change in walking function among patients with PAD undergoing BFR training. The investigators will assess change in Six-Minute Walk Test (6MWT) distance from baseline to post-intervention and 3-month follow-up to compare functional improvements between the BFR group and the two control groups\n2. Assess changes in health-related quality of life among patients with PAD undergoing BFR training. The investigators will use the EuroQol 5-Dimension 5-Level (EQ-5D-5L) scale to evaluate quality-of-life changes from baseline to post-intervention and 3-month follow-up across all study arms\n3. Evaluate the safety and feasibility of a supervised BFR training program for patients with PAD. The investigators will compare adverse event (AE) and serious adverse event (SAE) rates across study arms, while also monitoring sessional ratings of perceived exertion (RPE), dyspnea, and claudication pain as indicators of symptom response and exercise tolerance. Feasibility will be assessed through enrollment success, intervention adherence, and retention rates across groups",[209],"Peripheral Arterial Disease",{"date":211,"type":28},"2026-04-29",{"date":189,"type":28},{"date":214,"type":19},"2027-04-27",{"name":34,"class":35},{"id":217,"slug":218,"hasResults":11,"nctId":219,"briefTitle":220,"officialTitle":220,"acronym":221,"eligibilityCriteria":222,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":164,"enrollmentInfo":223,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":224,"conditions":225,"keywords":227,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":237,"lastUpdatePostDateStruct":238,"startDateStruct":240,"completionDateStruct":242,"leadSponsor":244,"locationsCount":36},"100577789","relationship-between-aspirin-metabolism-and-markers-of-metabolic-dysfunction-among-pregnant-persons-at-risk-of-pre-eclampsia-100577789","NCT06802861","Relationship Between Aspirin Metabolism and Markers of Metabolic Dysfunction Among Pregnant Persons at Risk of Pre-eclampsia","RAMP","Inclusion Criteria:\n\n* Recommended aspirin for pre-eclampsia prevention by OB\u002FGYN or MFM specialist based on ACOG and USPSTF guidelines (1 high risk factor, 2+ moderate risk factors)\n\n  * Willingness to adhere to aspirin therapy\n  * Willingness to undergo 2h OGTT for serum and urine collection in addition to survey collection, indirect calorimetry, body composition measures, neonatal measures, etc.\n  * Gestational age at enrollment \\\u003C16 weeks\n  * Ability to speak, read, and communicate via English\n\nExclusion Criteria:\n\n* Type 2 Diabetes Mellitus\n\n  * Type 1 Diabetes Mellitus\n  * Current gestational diabetes mellitus\n  * Current\u002Factive platelet disorder or bleeding diathesis (thrombocytopenia of any etiology, idiopathic thrombocytopenic purpura\u002FITP, thrombotic thrombocytopenic purpura\u002FTTP, von Willebrand disease, etc.)\n  * Thrombophilia\n  * Current use of NSAID for other indication (indomethacin, ibuprofen, etc.)\n  * Current use of other immune-modulating agents and biologics (hydroxychloroquine, azathioprine, 6-mercaptopurine, IL-6 inhibitors, etc.)\n  * Current or recent use of steroids\n  * Current use of prophylactic or therapeutic anticoagulation\n  * Medical contraindication to aspirin therapy\n  * Molar pregnancy\n  * Renal disease\n  * Inability or unwillingness to give informed consent\n  * Current psychiatric illness\u002Fsocial situation that would limit compliance with study requirements, as determined by the principal investigators",{"count":18,"type":19},"This study's primary purpose is to determine the relationship between aspirin metabolism and markers of metabolic dysfunction among patients at risk for preeclampsia.",[169,171,172,226,178,179,173,174,180],"Obesity and Obesity-related Medical Conditions",[228,229,230,231,232,233,234,235,236],"metabolic dysfunction","gestational diabetes","pregnancy","maternal obesity","maternal insulin resistance","aspirin metabolism","GDM","substrate oxidation","gestational glucose intolerance","2025-09-03",{"date":239,"type":28},"2025-09-10",{"date":241,"type":28},"2025-01-01",{"date":243,"type":19},"2028-12-31",{"name":34,"class":35},{"id":246,"slug":247,"hasResults":11,"nctId":248,"briefTitle":249,"officialTitle":250,"acronym":4,"eligibilityCriteria":251,"healthyVolunteers":11,"sex":44,"minAge":16,"maxAge":252,"enrollmentInfo":253,"targetDuration":4,"studyType":48,"phases":255,"briefSummary":256,"conditions":257,"keywords":259,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":265,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":271,"locationsCount":36},"100604753","efficacy-of-perioperative-opioid-sparing-techniques-on-time-to-initiation-of-chemotherapy-100604753","NCT07153614","Efficacy of Perioperative Opioid Sparing Techniques on Time to Initiation of Chemotherapy","Efficacy of Perioperative Opioid Sparing Techniques on Time to Initiation of Chemotherapy: A Randomized Single Blinded Control Study","Inclusion Criteria:\n\n1. 18-80 years of age\n2. Patients undergoing open surgery for foregut, HPB, and colorectal cancer\n3. Able to read and understand study procedures\n4. Willing to participate and sign an ICF\n5. If female of childbearing potential, subject must have a negative pregnancy test\n6. Recommended for adjuvant chemotherapy\n7. Patients scheduled for an AM admit procedure\n8. English speaking\n9. Patients with a midline incision\n\nExclusion Criteria:\n\n1. Chronic Opioid Use (received an opioid within 90 days preoperatively)\n2. Recreational Drug Use\n3. Patients with cognitive impairments that can affect their ability to give consent\n4. Patients that are currently taking anti-coagulants \\\u003C7 days prior to surgery\n5. Pregnant or breastfeeding\n6. Does not require adjuvant chemotherapy\n7. Relative Contradictions for receiving a nerve block\\*\n8. Patients that have been admitted prior to surgery for chief complaint related to complications from malignancy\n9. Inability to provide consent\n\n   * Absolute Contraindications\n\n     * Lack of patient consent.\n     * Skin infection at the site of needle insertion. Relative Contraindications\n     * Coagulopathy\n     * Systemic infection\n     * Anatomical distortion\n     * Neuropathy\n\nDrugs\u002FDevice usage within 7 Days of Randomization if any:\n\n• Anticoagulants","80 Years",{"count":254,"type":19},200,[72],"The primary purpose of this study is to determine if intrathecal morphine (ITM) administration is superior to quadratus lumborum block or surgeon administered transversus abdominis plane (TAP) blocks result in decreased time to initiation of chemotherapy following oncologic surgery.\n\nThe secondary objectives of this study are to determine:\n\n* The difference between interventions in time to return of bowel function in days\n* The difference between interventions in incidence of opioid related adverse drug events (ORADEs)\n* The difference between interventions in cumulative and post-operative total morphine milligram equivalents\n* The difference between interventions in quality-of-life assessment tool and patient satisfaction (brief pain index short form BPI-sf9)\n* The difference between interventions in hospital length of stay in days\n* The difference between cumulative pain scores between interventions\n* The difference between short acting and long-acting bupivacaine in pain management and time to chemotherapy\n\nThe hypothesis is that preoperative intrathecal morphine administration will significantly reduce the time to initiation of postoperative chemotherapy.",[258],"Perioperative Opioid Sparing Techniques",[260,258,261,262,263],"Opioid","Colorectal Cancer","Foregut Cancer","Hepatopancreatobiliary (HPB)","2025-08-29",{"date":266,"type":28},"2025-09-04",{"date":268,"type":28},"2025-02-03",{"date":270,"type":19},"2027-02-03",{"name":34,"class":35},{"id":273,"slug":274,"hasResults":11,"nctId":275,"briefTitle":276,"officialTitle":277,"acronym":278,"eligibilityCriteria":279,"healthyVolunteers":11,"sex":44,"minAge":16,"maxAge":4,"enrollmentInfo":280,"targetDuration":4,"studyType":48,"phases":282,"briefSummary":283,"conditions":284,"keywords":287,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":291,"lastUpdatePostDateStruct":292,"startDateStruct":294,"completionDateStruct":296,"leadSponsor":298,"locationsCount":36},"100589378","quadratus-lumborum-versus-placebo-in-open-ventral-hernia-repair-100589378","NCT06953635","Quadratus Lumborum Versus Placebo in Open Ventral Hernia Repair","Quadratus Lumborum Blocks for Pain Control Following Open Ventral Hernia Repair: A Double Blinded Randomized Control Trial","VHR","Inclusion Criteria:\n\n1. \\>18 years of age\n2. Able to read and understand study procedures\n3. Willing to participate and sign an informed consent form\n4. Open approaches to ventral hernia repair\n5. Clean (CDC Class I), clean-contaminated (CDC Class II)\n6. Elective surgery\n7. Mesh placed in the retromuscular position\n\nExclusion Criteria:\n\n1. Dirty-Infected cases (CDC Class IV): Old traumatic wounds with retained devitalized tissue and those that involve existing clinical infection or perforated viscera\n2. Patient has a contraindication to receiving the drug and\u002For procedure: allergy\u002Fsensitivity to the drug, coagulopathy, abdominal wall infection at the drug administration site, systemic infection, anatomical distortion, neuropathy\n3. Emergent procedure\n4. Mesh not placed",{"count":281,"type":19},70,[72],"The purpose of this study is to determine whether using a QL block is better than placebo (a look-alike substance that contains no drug) in lowering the amount of opioids you need for pain relief in the first 24 hours and if it improves your recovery following a ventral hernia repair.\n\nParticipants will be asked to complete a questionnaire before surgery and again at their 30-day follow up. You will also be asked to complete a pain diary 24 hours after surgery and attend a follow-up visit approximately 30 days after surgery.\n\nThe following information will be collected from you or your medical record:\n\n1. Pain medications given to you during surgery.\n2. Pain medications prescribed to you after surgery, including medication name, dose, units, and frequency.\n3. Pain levels during the first 24 hours after surgery.\n4. Your total hospital length of stay after surgery.\n5. Any complications that you may have experienced after surgery.\n6. Demographic information, medical history as well as details about your hernia repair surgery.",[285,286],"Hernia, Ventral","Pain Management",[288,289,290],"Regional Anesthesia","Postoperative Pain","Ventral Hernia Repair","2025-04-29",{"date":293,"type":28},"2025-05-01",{"date":295,"type":19},"2025-06-01",{"date":297,"type":19},"2026-02-28",{"name":34,"class":35},{"id":300,"slug":301,"hasResults":11,"nctId":302,"briefTitle":303,"officialTitle":303,"acronym":4,"eligibilityCriteria":304,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":305,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":307,"conditions":308,"keywords":4,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":310,"lastUpdatePostDateStruct":311,"startDateStruct":313,"completionDateStruct":315,"leadSponsor":317,"locationsCount":36},"100577577","dysregulation-of-whole-body-metabolism-in-ovarian-cancer-a-longitudinal-study-100577577","NCT06800105","Dysregulation of Whole-body Metabolism in Ovarian Cancer: A Longitudinal Study","Inclusion Criteria:\n\n* Women\n* Age \\>18\n* Presumed ovarian cancer diagnosis (i.e. those being clinically evaluated for suspicion of ovary cancer)\n* Planned treatment course for ovarian cancer involving cytoreductive surgery followed by chemotherapy\n* Availability to commit to attending all study visits\n* Internet access and consistent access to phone\u002Femail\u002Ftext communication\n\nExclusion Criteria:\n\n* Pregnancy\n* Inability to provide voluntary informed consent\n* Inability to consume the pre-study visit meal\u002Fsnack and\u002For the study visit meal due to strict dietary restrictions\n* Illicit substance use (e.g. cocaine, methamphetamines, heroin, street drugs) - marijuana and CBD oil and related supplements will be considered on a case-by-case basis by the principal investigators\n* Circumstances and\u002For medical condition that would limit compliance with study requirements and protocol, as determined by the principal investigators",{"count":306,"type":19},10,"Minimal information is available regarding changes in whole-body metabolism in ovarian cancer patients, and no study has assessed whole-body lipid metabolism in this patient population. In this pilot study we will assess fasting and postprandial lipid metabolism of ovarian cancer patients before, during, and after treatment via indirect calorimetry.",[309],"Ovary Cancer","2025-01-23",{"date":312,"type":28},"2025-01-29",{"date":314,"type":28},"2023-03-22",{"date":316,"type":19},"2028-03-31",{"name":34,"class":35},""]